Ovarian Neoplasms
2 competing products in clinical development for Ovarian Neoplasms.
Pipeline by Phase
Phase 11
Phase 21
All Products (2)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| LY4337713 | Eli Lilly | Phase 1 | Recruiting | 36 |
| OSI-211 (Liposomal Lurtotecan) | Astellas Pharma | Phase 2 | Completed | 35 |